Alpine Immune Sciences, Inc.
ALPNDelisted May 20, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001626199
Alpine Immune Sciences, Inc. was delisted on May 20, 2024; its insiders filed their last Form 4 on May 20, 2024; 181 institutions reported holding it in 13F filings for Q1 2024, worth $2.56B in total; no superinvestor held it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 181
- Q1 2024, +48 vs. previous quarter
- 13F value
- $2.56B
- Reported value at the end of Q1 2024
- Superinvestors holding
- 0
- At the end of Q1 2024
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2023
- $58.9M
- +95.8% year over year
- Net income, FY2023
- -$32.2M
- No comparable prior period
- Free cash flow, FY2023
- -$79.5M
- No comparable prior period
- Revenue, Q1 FY2024
- $7.03M
- −25.1% year over year
Revenue flow, FY2023
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2023: $32.2M (54.7% of revenue).
Superinvestors holding ALPN, Q1 2024
Go to the superinvestors tabNo superinvestor reported holding ALPN at the end of Q1 2024.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Alpine Immune Sciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2024 (view filing) | Apr 25 | 4 days | Topper James NDirector | SSale | −19 | $64.57 | −$1.23K | 0.0%2.83M after | |
| Jan 29, 2024 (view filing) | Jan 25-26 | 4 days | Rickey James PaulSee Remarks | SSale | −118.0K | $23.31 | −$2.75M | −100.0%0 after | 3 lots10b5-1 |
| Dec 29, 2023 (view filing)4:18 PM ET | Dec 27-28 | 2 days | OrbiMed Advisors LLC and 2 othersDirector | SSale | −1.55M | $18.54 | −$28.7M | −85.4%264.3K after | 6 lotsDuplicate filing |
| Dec 29, 2023 (view filing) | Dec 28 | 1 day | Gold MitchellExecutive Chairman and CEO | SSale | −1.02K | $20.04 | −$20.4K | −100.0%0 after | 10b5-1 |
| Dec 29, 2023 (view filing) | Dec 27-28 | 2 days | Thompson Peter A.Director | SSale | −1.55M | $18.54 | −$28.7M | −85.4%264.3K after | 6 lots |
| Dec 27, 2023 (view filing)9:07 PM ET | Dec 22-27 | 5 days | Gold MitchellExecutive Chairman and CEO | SSale | −91.9K | $20.25 | −$1.86M | −100.0%0 after | 3 lots10b5-1 |
| Dec 21, 2023 (view filing)7:34 PM ET | Dec 19 | 2 days | Gold MitchellExecutive Chairman and CEO | SSale | −2.40K | $20.01 | −$48.1K | −100.0%0 after | 10b5-1 |
| Dec 21, 2023 (view filing) | Dec 19 | 2 days | Rickey James PaulSee Remarks | SSale | −15.2K | $19.21 | −$292.2K | −100.0%0 after | 10b5-1 |
| Dec 18, 2023 (view filing) | Dec 14-18 | 4 days | Rickey James PaulSee Remarks | SSale | −58.8K | $19.07 | −$1.12M | −100.0%0 after | 3 lots10b5-1 |
| Dec 12, 2023 (view filing)9:02 PM ET | Dec 8-12 | 4 days | Gold MitchellExecutive Chairman and CEO | SSale | −118.0K | $17.27 | −$2.04M | −100.0%0 after | 4 lots10b5-1 |
Top 10 13F holders, Q1 2024
See all 181 holdersThe largest institutional positions in Alpine Immune Sciences, Inc. at the end of Q1 2024; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Decheng Capital LLC | 8,317,924 | $329.7M | 44.22% | +1,234,636+17.4% | Added |
| Avoro Capital Advisors LLC | 5,775,000 | $228.9M | 2.67% | +5,775,000 | New |
| BlackRock Inc. | 3,575,092 | $141.7M | 0.00% | +516,594+16.9% | Added |
| Frazier Life Sciences Management, L.P. | 3,131,008 | $124.1M | 5.24% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 3,080,220 | $122.1M | 0.01% | +1,392,942+82.6% | Added |
| State Street Corp | 2,845,839 | $112.8M | 0.01% | +1,455,810+104.7% | Added |
| Vanguard Group Inc | 2,712,285 | $107.5M | 0.00% | +477,518+21.4% | Added |
| Cormorant Asset Management, LP | 2,700,000 | $107.0M | 4.72% | +150,000+5.9% | Added |
| OrbiMed Advisors LLC | 2,680,496 | $106.3M | 2.08% | +145,251+5.7% | Added |
| Lynx1 Capital Management LP | 2,253,183 | $89.3M | 23.00% | −1,560,743−40.9% | Reduced |